Trial
NCT02960217
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Ultragenyx Pharmaceutical Inc
Collaborators
—
Condition
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Intervention
UX007
Why stopped
Study was halted prematurely due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-16